FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907319352> ?p ?o ?g. }

• W2907319352 endingPage "1515" @default.
• W2907319352 startingPage "1515" @default.
• W2907319352 abstract "Abstract Background: Adhesion G-protein coupled receptor (aGPCR) is one of the five GPCRs families that are named after their large extracellular regions linked to the seven-transmembrane moiety (TM7) and are found to have a dual role in signaling and cell adhesion. In normal tissues, aGPCRs play important roles in neuronal development and the immune system. The aGPCR GPR56 has been reported to be involved in the hematopoiesis and the interaction between hematopoietic stem cells and the bone marrow. In malignant tissues, aGPCRs were reported to play a role in tumor cell migration and invasion of melanoma and prostate cancers, and are relevant to the regulation of angiogenesis in glioblastomas. Limited data are available related to the expression and role of aGPCRs in hematological malignancies, particularly in acute myeloid leukemia. Here, we aim to characterize the expression of aGPCRs in patients with AML and examine whether upregulation of genes in this family is associated with clinical and molecular patient's characteristics. Methods: We analyzed the TCGA data of 200 AML patients for which 173 have complete clinical and expression data available. We examined gene upregulation of the 33 aGPCRs and assessed the association between each gene and patient's overall survival (OS); genes that were significantly associated with shorter overall survival were combined in one signature (poor survival genes) for further analysis to test their association with patient's clinical and molecular characteristics and clinical outcome. To gain an insight into the mechanistic role of aGPCRs in AML, we conducted Ingenuity Pathway Analysis (IPA) to identify potential pathways common among the poor survival aGPCR genes, and between the aGPCRs genes and AML frequently mutated genes. Results: Among the 33 aGPCRs; eight were found to be associated with worse clinical outcome. Patients with high expression (Z≥1) in one of the eight genes have significantly shorter median overall survival and disease-free survival (DFS) compared with patients with low (Z<1) expression of that gene (ADGRB1: OS 8.20 vs 21.50 months, p=0.0157; CELSR2: OS 10.00 vs 21.50 months, p=0.0488; ADGRD1: OS 11.10 vs 20.50 months, p=0.0085; ADGRE1: OS 10.60 vs 20.50 months, p=0.0198; ADGRE2: DFS 12.10 vs 18.20 months, p=0.0374; ADGRE5: OS 7.35 vs 24.10 months, p=0.0015; ADGRG1: OS 6.80 vs 22.30 months, p=0.0057; ADGRG3: OS 10.00 vs 21.50 months, p=0.0177). Among the 200 samples in TCGA data; 118 (72.8%) of 162 sequenced patients have an alteration in at least one of these eight genes with a minimum 10% alternation in ADGRD1 to a maximum 33% alternation in ADGRE2, most of them are upregulation. When we combined all eight genes in one signature for further analysis; we found that patients with high expression (Z≥1) in any of the eight genes (ADGRB1, CELSR2, ADGRD1, ADGRE1, ADGRE2, ADGRE5, ADGRG1, ADGRG3), have significantly shorter overall survival or disease-free survival compared with patients with low (Z<1) expression of all eight aGPCR genes (median OS:11.8 vs 55.4 months; p< 0.0001). Next, we examined the association between the expression of eight aGPCRs with patient primary and molecular characteristics. High expression of the eight aGPCRs was significantly associated with older age (≥60; p=0.011). Patients with high aGPCRs are more frequently classified in the poor risk status group and less in the good risk group compared with patients with low aGPCRs levels (31% vs 17% p=0.049 and 14% vs 28% p=0.027, respectively). Multivariate analyses showed that high (Z≥1) aGPCRs expression was associated with shorter overall survival in patients with AML (HR:1.73, 95% CI 1.11-2.69; p=0.015) after adjusting by age, molecular risk, and transplant status. Using IPA analysis, we identified the SNX27 gene, to connect three of the eight aGPCRs. SNX27 is a member of sorting nexin protein family and is implicated in endocytic trafficking. Importantly, we found that patients with low (Z≤-1) expression of SNX27 have a significantly shorter overall survival compared with patients with Z>-1 (median OS: 8.10 vs 20.50 months, p=0.0251). Conclusion: Overall, our data suggest that particular aGPCRs are frequently upregulated in AML and that their overexpression is associated with poor clinical outcome. Future functional and mechanistic analysis are needed to address the role of aGPCRs in AML. Disclosures No relevant conflicts of interest to declare." @default.
• W2907319352 created "2019-01-11" @default.
• W2907319352 creator A5003617778 @default.
• W2907319352 creator A5027341625 @default.
• W2907319352 creator A5054514509 @default.
• W2907319352 date "2018-11-29" @default.
• W2907319352 modified "2023-09-28" @default.
• W2907319352 title "Characterization of Upregulated Adhesion GPCRs in Acute Myeloid Leukemia" @default.
• W2907319352 doi "https://doi.org/10.1182/blood-2018-99-119998" @default.
• W2907319352 hasPublicationYear "2018" @default.
• W2907319352 type Work @default.
• W2907319352 sameAs 2907319352 @default.
• W2907319352 citedByCount "0" @default.
• W2907319352 crossrefType "journal-article" @default.
• W2907319352 hasAuthorship W2907319352A5003617778 @default.
• W2907319352 hasAuthorship W2907319352A5027341625 @default.
• W2907319352 hasAuthorship W2907319352A5054514509 @default.
• W2907319352 hasBestOaLocation W29073193521 @default.
• W2907319352 hasConcept C104317684 @default.
• W2907319352 hasConcept C109159458 @default.
• W2907319352 hasConcept C127561419 @default.
• W2907319352 hasConcept C203014093 @default.
• W2907319352 hasConcept C2778461978 @default.
• W2907319352 hasConcept C2778729363 @default.
• W2907319352 hasConcept C2779282312 @default.
• W2907319352 hasConcept C2780007613 @default.
• W2907319352 hasConcept C2780394083 @default.
• W2907319352 hasConcept C28328180 @default.
• W2907319352 hasConcept C502942594 @default.
• W2907319352 hasConcept C54355233 @default.
• W2907319352 hasConcept C86803240 @default.
• W2907319352 hasConcept C95444343 @default.
• W2907319352 hasConceptScore W2907319352C104317684 @default.
• W2907319352 hasConceptScore W2907319352C109159458 @default.
• W2907319352 hasConceptScore W2907319352C127561419 @default.
• W2907319352 hasConceptScore W2907319352C203014093 @default.
• W2907319352 hasConceptScore W2907319352C2778461978 @default.
• W2907319352 hasConceptScore W2907319352C2778729363 @default.
• W2907319352 hasConceptScore W2907319352C2779282312 @default.
• W2907319352 hasConceptScore W2907319352C2780007613 @default.
• W2907319352 hasConceptScore W2907319352C2780394083 @default.
• W2907319352 hasConceptScore W2907319352C28328180 @default.
• W2907319352 hasConceptScore W2907319352C502942594 @default.
• W2907319352 hasConceptScore W2907319352C54355233 @default.
• W2907319352 hasConceptScore W2907319352C86803240 @default.
• W2907319352 hasConceptScore W2907319352C95444343 @default.
• W2907319352 hasIssue "Supplement 1" @default.
• W2907319352 hasLocation W29073193521 @default.
• W2907319352 hasOpenAccess W2907319352 @default.
• W2907319352 hasPrimaryLocation W29073193521 @default.
• W2907319352 hasRelatedWork W1516501920 @default.
• W2907319352 hasRelatedWork W1982854051 @default.
• W2907319352 hasRelatedWork W2076188533 @default.
• W2907319352 hasRelatedWork W2115640225 @default.
• W2907319352 hasRelatedWork W2121159001 @default.
• W2907319352 hasRelatedWork W2260322567 @default.
• W2907319352 hasRelatedWork W2513610256 @default.
• W2907319352 hasRelatedWork W2520871879 @default.
• W2907319352 hasRelatedWork W3135157890 @default.
• W2907319352 hasRelatedWork W4210379329 @default.
• W2907319352 hasVolume "132" @default.
• W2907319352 isParatext "false" @default.
• W2907319352 isRetracted "false" @default.
• W2907319352 magId "2907319352" @default.
• W2907319352 workType "article" @default.